Altered Gene Expression Profile in Mouse Bladder Cancers Induced by Hydroxybutyl(butyl)nitrosamine  by Yao, Ruisheng et al.
Altered Gene Expression Profile in Mouse Bladder Cancers
Induced by Hydroxybutyl(butyl)nitrosamine
Ruisheng Yao*, William J. Lemon*, Yian Wang*, Clinton J. Grubbs y, Ronald A. Lubet z and Ming You*
*Department of Surgery and The Alvin J. Siteman Cancer Center, Campus Box 8109, Washington University
School of Medicine, St. Louis, MO 63110, USA; yDepartments of Surgery, Genetics, and Medicine, University
of Alabama at Birmingham, Birmingham, AL 35294, USA; zChemoprevention Agent Development Research
Group, National Cancer Institute, Rockville, MD 20892, USA
Abstract
A variety of genetic alterations and gene expression
changes are involved in the pathogenesis of bladder
tumor. To explore these changes, oligonucleotide array
analysis was performed on RNA obtained from carcino-
gen-induced mouse bladder tumors and normal mouse
bladder epithelia using Affymetrix (Santa Clara, CA)
MGU74Av2 GeneChips. Analysis yielded 1164 known
genes that were changed in the tumors. Certain of the
upregulated genes included EGFR–Ras signaling
genes, transcription factors, cell cycle–related genes,
and intracellular signaling cascade genes. However,
downregulated genes include mitogen-activated pro-
tein kinases, cell cycle checkpoint genes, Rab sub-
family genes, Rho subfamily genes, and SH2 and SH3
domains–related genes. These genes are involved in
a broad range of different pathways including control
of cell proliferation, differentiation, cell cycle, signal
transduction, and apoptosis. Using the pathway visual-
ization tool GenMAPP, we found that several genes,
including TbR-I, STAT1, Smad1, Smad2, Jun, NFnB,
and so on, in the TGF-b signaling pathway and p115
RhoGEF,RhoGDI3,MEKK4A/MEKK4B, PI3KA, and JNK
in the G13 signaling pathway were differentially ex-
pressed in the tumors. In summary, we have deter-
mined the expression profiles of genes differentially
expressed during mouse bladder tumorigenesis. Our
results suggest that activation of the EGFR–Ras
pathway, uncontrolled cell cycle, aberrant transcription
factors, and G13 and TGF-b pathways are involved, and
the cross-talk between these pathways seems to play
important roles in mouse bladder tumorigenesis.
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Introduction
Bladder cancer is the fifth most common cancer in the
United States and is associated with exposure to cigarette
smoke; it is predicted to account for 57,400 new cases and
12,500 cancer-related deaths in 2003. Approximately 15%
of bladder tumors evolve into invasive tumors after infiltration
through the basement membrane. Patients with muscle inva-
sive disease are at high risk for recurrence, progression, and
metastases. The incidence of bladder cancer has been steadily
increasing and, despite improvements in treatment, the major-
ity of the patients will not survive for 5 years [1].
Ras, erb-B2, and epidermal growth factor receptor (EGFR)
are the most important oncogenes in urinary bladder cancer.
The transforming potential of ras is due to a mutation, whereas
EGFR and erb-B2 are commonly overexpressed in trans-
formed cells. Reported frequencies of H-ras point mutations
with a glycine-to-valine substitution in codon 12 in bladder neo-
plasms varied widely between studies from 0% to 45% [2–5].
Recently, several ways to suppress Ras activities, including
inhibitors of Ras signal transduction and a ras suppressor
mutant, have been reported [6]. Overexpression of EGFR or
erb-B2 and ras mutation could result in constitutive MAPK acti-
vation [7] and correlates with muscular invasion and extent of
tumor invasion [8]. Almost all advanced bladder carcinomas
lack either pRb or p16INK4a, with cyclin D1 overexpression pref-
erentially occurring in earlier stages [9,10].
There are two primary chemically induced models of urinary
bladder cancers in rodents. Both employ repeated intragastric
administration of 4-hydroxybutyl(butyl)nitrosamine (OH-BBN)
to induce bladder cancers in either mice or rats [11,12]. The
bladder cancers typically have a mixed histology showing ele-
ments of both transitional and squamous cells. Investigators
have found a relatively low frequency of Ras mutation in these
cancers [13] and roughly 50% of these tumors develop p53
mutations [14], which are similar to those found in humans.
Complete loss of p53 is a prerequisite for collaborating with
activated Ha-ras to promote bladder tumorigenesis [15]. Inac-
tivation of p53 and pRb induced carcinoma in situ and invasive
and metastatic bladder cancer, whereas activation of Ha-ras in
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transgenic mice caused urothelial hyperplasia and super-
ficial papillary noninvasive bladder tumors. These results
provide strong, direct experimental evidence that the two
phenotypic pathways of bladder tumorigenesis are caused
by distinctive genetic defects [16]. There has been further
characterization of these tumors for various gene products
of the EGFR loop [17]. Similar to human bladder tumors,
these tumors tend to show overexpression of EGFR and
amphiregulin.
Significant progress has been made in understanding the
underlying molecular and genetic events in bladder cancer.
Numerous markers have been described to correlate to
some extent with tumor stage and prognosis of patients with
bladder cancer. However, the power of many of these
markers is limited; there remains a great need to develop
reliable alternative markers that can provide more useful
information regarding diagnosis and prognosis, and to facil-
itate the selection of appropriate therapy in the individual
patient. Expression profiling with high-throughput DNA
microarrays has the potential of providing critical clues. In
this study, we employed Affymetrix (Santa Clara, CA) micro-
arrays representing over 12,000 genes and expressed se-
quence tags (ESTs) to identify differentially expressed genes
in mouse bladder tumors. The purposes of the present study
were: 1) to detect and identify differential gene expression
profiles in mouse bladder tumors; and 2) to elucidate the
underlying mechanisms of mouse bladder tumorigenesis.
The genes identified in this study can be employed in a
variety of applications: 1) for use as early detection markers
for bladder lesions in the mouse model; 2) for comparison of
gene expression changes observed in mouse to human
bladder cancers; 3) for basic understanding of the bladder
cancer process; 4) for help in defining potential molecular
targets, which can be tested in therapeutic or prevention
studies in bladder tumor models; and 5) for use as potential
modulatable biomarkers, which can be employed in screen-
ing for potential agents, or in determining the efficacy of
those agents.
Materials and Methods
Mouse Bladder Tumors
Male B6D2F1 (C57Bl/6  DBA/2 F1)micewere obtained
from Harlan Sprague–Dawley, Inc. (Indianapolis, IN) at 28
days of age and were housed in polycarbonate cages (five
per cage). The animals were kept in a lighted room 12 hours
each day andmaintained at 22 ± 0.5jC. Teklad 4%mash diet
(Harlan Teklad,Madison,WI) and tapwater were provided ad
libitum. At 56 days of age, mice received the first of 12 weekly
gavage treatments with OH-BBN (TCI America, Portland,
OR). Each 7.5-mg dose was dissolved in 0.1 ml of ethanol:-
water (25:75). Mice (unless sacrificed early because of a
large palpable bladder mass) were sacrificed 8 months fol-
lowing the first OH-BBN treatment. Bladder tumors were
removed and frozen for subsequent molecular assays. A
portion of each tumor was fixed and processed for routine
paraffin embedding, cut into 5-mm sections, and mounted for
hematoxylin and eosin (H&E) staining for histopathology. All
bladder tumors used in this study were diagnosed as bladder
cancers with a mixed histology showing elements of both
transitional and squamous cells. Both bladder tissues and
normal bladder epithelia come from age-matched controls.
RNA Isolation and Amplification
To isolate bladder epithelia, we conducted microdissec-
tion, under a dissecting microscope employing control mice
who were at least 8 months old, by separating the epithelia
from the stroma and muscle tissues using surgical blade and
forceps. A 5-mm frozen section was made and H&E–stained
to examine the purity of the isolated epithelia. Total RNA from
normal bladder epithelia, normal bladder tissues, and bladder
cancers were isolated by Trizol (Invitrogen, Carlsbad, CA)
and purified using the RNeasy Mini Kit and RNase-free
DNase Set (QIAGEN, Valencia, CA) according to the manu-
facturer’s protocol. In vitro transcription-based RNA amplifi-
cation was then performed on each sample. cDNA for each
samplewas synthesized using aSuperscript cDNASynthesis
Kit (Invitrogen) and a T7-(dT)24 primer: 5V-GGCCAGT-
GAATTGTAATACGACT-CACTATAGGGAGGCGG-(dT)24-
3V. The cDNA was cleaned using phase-lock gel (Fisher Cat
ID E0032005101) phenol/chloroform extraction. Then, the
biotin-labeled cRNAwas transcribed in vitro from cDNA using
a BioArray High Yield RNA Transcript Labeling Kit (ENZO
Biochemistry, New York, NY) and purified, again using the
RNeasy Mini Kit.
Affymetrix GeneChip Probe Array and Semiquantitative
Reverse Transcription Polymerase Chain Reaction
(RT-PCR) Confirmation
The labeled cRNAwas applied to the Affymetrix Mu74Av2
GeneChips, which contain >12,000 genes and ESTs on one
array according to the manufacturer’s recommendations.
Every gene or EST is represented by a probe set consisting
of approximately 16 probe pairs (oligonucleotides) of 25-mer
oligonucleotides. One sequence of a probe pair represents
the complementary strand of the target sequence, whereas
the other has a 1-bp mismatch at the central base pair
position. This mismatch sequence serves as an internal
control for specificity of hybridization. To evaluate the reli-
ability of the array results, 10 genes were randomly selected
from the genes detected in the microarray assay for further
confirmation by semiquantitative RT-PCR as previously de-
scribed [18]. The large number of differentially expressed
genes led us to take a further quality control step in which the
distribution of fold changes was examined.
Grouping Gene
Genes were functionally annotated using the GO-Biologic
Process annotations as provided by Affymetrix. To organize
the differentially expressed genes into a small number of
mutually exclusive categories, each GO category repre-
sented in the data set was mapped to 1 of 14 categories of
Table 1. This mapping resulted in genes that were catego-
rized either unambiguously, ambiguously, or not at all.
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Genes with no or ambiguous categorization were examined
and manually placed in 1 of 14 categories.
Cluster and GenMAPP
Array normalization and gene expression estimates were
obtained using Affymetrix Microarray Suite 5.0 software
(MAS5). The array mean intensities were scaled to 1500.
These estimates formed the basis for statistical testing. To
eliminate the false calls of the gene expression, the raw data
values below 300 were excluded from the data set. Differ-
ential expression was determined using the combined basis
of t-test with P < .05 and fold changes (either up or down)
greater than two-fold. Thus, for a gene to be included in our
list, it had to be expressed at moderate to high levels and
display at least a two-fold alteration in expression, and that
difference had to be statistically significant. Genes meeting
all these criteria were called positive for differential expres-
sion. Hierarchical clustering was performed as follows. For
the selected genes, expression indexes were transformed
across samples to an N(0,1) distribution using a standard
statistical Z-transform. These values were inputted to the
GeneCluster program of Eisen et al. [19] and genes were
clustered using average linkage and correlation dissimilarity.
Signal transduction pathways, metabolic pathways, and
other functional groupings of genes were evaluated for
differential regulation using the visualization tool GenMAPP
[20]. We imported the statistical results of our data set into
the program and used GenMAPP to illustrate pathways
containing differentially expressed genes.
Results
Different Expression Patterns between Epithelia and Whole
Tissues
The experiment design for this study includes the use of
mouse bladder epithelium, bladder tissue, and bladder tumor
to test the usefulness of whole bladder tissues versus purif-
ied epithelium as controls, and to profile the gene differential
expression during the mouse bladder tumorigenesis. Untu-
tored cluster diagrams of whole mouse bladder tissues,
epithelia, and tumors, and dendrograms were created from
hierarchical clustering of the gene expression profiles of each
sample. The whole bladder tissues, epithelia, and tumors
were clustered in groups by tissue type (Figure 1). Comparing
the epithelium with the tumors, 1554 genes were found to
be differentially expressed in the tumors. When comparing
whole bladder tissues and tumors, 805 genes were found to
be differentially expressed in tumors. About 51.8% of 1554
genes found in tumors with epithelium controls had the same
results as with whole bladder controls (Figure 1). There were
also another 456 genes found to be differentially expressed
when using whole bladder as controls, which did not show
changes when using epithelium controls (data not shown).
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Table 1. Classification of 1164 Known Genes Found to Be Differentially
Expressed in Mouse Bladder Cancers by Microarray Analysis (Fold Change
z 2 and P < .05) Into 14 Subgroups Using the GO-Biological Process
Annotations as Provided by Affymetrix.
Group Description Number of Genes
Changed in Tumors
Up Down
1 Cell cycle 42 10
2 Immune response 99 7
3 Transcription 54 47
4 G-protein signaling 23 8
5 Cell adhesion 42 9
6 Small GTPase signaling 13 16
7 Other signaling effectors 43 24
8 Transport 40 36
9 Metabolism 112 129
10 Apoptosis 13 8
11 Development/differentiation 20 25
12 Cell proliferation 23 12
13 Cytoskeleton 20 22
14 Others 15 6
Total annotated 559 359
Total unannotated 144 102
Figure 1. Comparison of bladder epithelia and whole bladder tissues as
controls to bladder cancers. Untutored clusters of whole mouse bladder
tissues, epithelia, and tumors were created from hierarchical clustering of the
gene expression profiles of each sample. Among the 1554 genes found
differentially expressed in mouse cancers compared with epithelia, 51.8%
genes were consistent between epithelium and whole tissues as controls. E,
bladder epithelium; N, whole bladder tissue; T, bladder tumor.
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Further comparisons are made with epithelium controls,
unless otherwise noted.
Gene Expression Profile in Bladder Tumors
In this study, microarray data were available from five
mouse bladder tumors and four mouse bladder normal
epithelia samples; fold changes of gene expression were
based on the ratios of mean values between tumors and
epithelium controls. Among 1554 differentially expressed
genes, 867 genes were overexpressed and 687 genes were
underexpressed in bladder tumors, and 1164 are known
genes. We categorized these genes into 14 subgroups, as
given in Table 1. Many of the upregulated genes were Ras
family genes, transcription factors, cell cycle–related genes,
and intracellular signaling cascades (Table 2). Downregu-
lated genes include the mitogen-activated protein kinase
genes, cell cycle checkpoint genes, Rab subfamily genes,
Rho subfamily genes, and SH2 and SH3 domains–related
genes (Table 3).
Gene Distribution and RT-PCR Confirmation
With such a large number of differentially expressed
genes, we examined the distribution of fold changes to detect
if any large skew could account for the results. The distribu-
tion of fold changes for the differentially expressed genes
is shown in Figure 2A, and its symmetry suggests that no
skew artifact is present. We validated the differential expres-
sion of 10 genes by semiquantitative RT-PCR. Nine of 10
genes were confirmed by RT-PCR. The confirmation rate
is 90% at the cutoff of two-fold change and P < .05. The RT-
PCR results of these nine genes agreed well with the micro-
array data (Figure 2B).
Ras-Related Genes in Bladder Tumors
Tables 2 and 3 list selected genes that were upregulat-
ed or downregulated, respectively. The Ras superfamily is a
diverse group of small G proteins participating in many cel-
lular processes and also widely involved in tumorigenesis. In
this study, many Ras superfamily members were found to
be abnormally expressed in bladder tumors. Except for
the Rab subfamily, including Rab3D, Rab9, Rab11A, and
Rab33B, which were underexpressed, almost all other ras-
related genes, such as Ras, Rap, Rin, Rac, Ran, and Rad,
were overexpressed in bladder tumors. For Rho-related
genes, Rho-GEF1 and RhoIP3 were overexpressed, and
Rho-GDIa, Rho-GDI, and RhoB were underexpressed in
mouse bladder tumors.
Cell Cycle–Related Genes and Transcription Regulators
in Bladder Tumors
Many of the overexpressed genes were cell cycle–relat-
ed genes that promote the entry into cell cycle and mitosis,
including cyclin B1, B2, D1, E1, CDK2, CDC2, CDC20,
CDC25, and CDC28 protein kinase 1. Cyclin G1, retinoblas-
toma (Rb)– like 2, ATM, Gas1, and Rb-binding protein 7
were found to be downregulated in mouse bladder tumors;
these genes play important roles in the cell cycle arrest and
G1/S and G2 checkpoints. Several genes that function in
cell cycle as transcription regulators, and which are associ-
ated with carcinogenesis in various cancers, were also over-
expressed in mouse bladder tumors. These genes included
ets, fos, Jun, myb, N-myc, NF-jB1, and IjB-e. In mouse
bladder tumors, we also found some transcription regulators
that function in normal development and differentiation to
be downregulated, including LMO1 and LMO4, GATA-BP2,
GATA-BP3, and GATA-BP4 (Tables 2 and 3).
Differentially Expressed Genes Interpreted by GenMAPP
GenMAPP is a tool for visualizing expression data in the
context of biologic pathways [20]. Using the GenMAPP, we
found MAPK cascade, G protein signaling pathway, apopto-
sis, Wnt signaling pathway, and TGF-b signaling, each of
which may be involved in bladder tumorigenesis. Figure 3
represents the genes differentially expressed in the mouse
bladder tumors that are involved in G13 and TGF-b signaling
pathways.
Discussion
One question for gene expression analysis both in human
and animal studies is the type of normal tissues to use as
controls. This problem is acute in complex tissues, such as
lung, prostate, and mammary tissues, in which the stroma is
mixed with the epithelium cells. For the whole organ, the epi-
thelium may only account for less than 20%. In these sit-
uations, is it reasonable to use the whole tissue as the
control? Our results reveal that when the whole bladder
tissues rather than the epithelia are used as controls, only
51.8% of the 1554 genes that changed in tumors compared
with the epithelia were found to be differentially expressed.
Another 456 genes were also found to be differentially
expressed when using whole bladder as controls (data not
shown). However, these 456 genes did not show any
changes when comparing tumors versus partially purified
epithelia. Our results indicate that numerous genes account-
ing for cellular diversity would also be interpreted as tumor-
igenesis genes when using whole bladder tissues as controls
in the study. Thus, it would appear that by preferentially
examining genes whose expression was altered both when
comparing tumors versus normal bladder and tumors ver-
sus isolated bladder epithelia, we may achieve a subset of
genes that might be particularly useful as biomarkers or
modulatable surrogate endpoints.
The transformation of normal cell into malignant cell is a
multistep process that involves mutations or chromosomal
aberrations. Like most types of cancer, the generation of
bladder cancer is caused by the accumulation of various
molecular changes, which can be categorized into 1) chro-
mosomal alterations; 2) loss of cell cycle regulation, resulting
in altered cellular proliferation; 3) growth control events such
as angiogenesis, resulting in metastasis; and 4) decreases in
cellular apoptosis. It is becoming apparent that the accumula-
tion of genetic and epigenetic changes ultimately determines
a tumor’s phenotype and subsequent clinical behavior.
Ras, erb-B2, and EGFR are the most important onco-
genes in bladder cancer. Ras superfamily regulates many
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cellular processes, such as cell cycle progression, actin
cytoskeletal dynamics, and membrane traffic. The trans-
forming potential of ras is due to a mutation, which, in bladder
tumors, occurs in H-ras [21]. Overexpressions of H-ras,
K-ras, and N-ras transcripts have also been associated with
bladder tumor transition [22,23]. Guanine nucleotide ex-
change factors (GEFs) stimulate Ras superfamily members
to exchange bound GDP for GTP, thereby increasing the
amount of active form [24]. EGFR is known to signal, at least
in part, through H-ras activation. A potential role for either a
normal or a mutated overexpressed H-ras in upregulating
EGFR during the progression of human bladder cancer to
invasive phenotype has been demonstrated in the human
papillary TCC cell line [25]. Rho family gene mutations in
tumors are quite rare, but overexpression is more common
[26]. Dysregulation of Rho family member activity probably
also contributes to human cancer, in that someRhoGEFs act
as oncogenes [27], whereas RhoGAPs [28] act as tumor
suppressors. Reduced expression of RhoGDIs has recently
been shown to correlate with increasing invasive and meta-
static ability in human bladder carcinoma cell lines [29,30].
Increased activity of another Ras effector, PI3 kinase, is
associated with many types of human cancer. Because PI3
kinase is an immediate downstream effector of Ras and
EGFR, multiple pathways may contribute to an increase in
PI3 kinase activity in bladder cancer. PI3 kinase consistently
prevents apoptosis in many cell systems through activation
of the Rac GTPase, possibly through activation of NF-nB
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Table 2. Selected Genes Whose Expression Is Upregulated in Mouse
Bladder Tumors Compared with Normal Bladder Epithelia Identified by
Microarray.
Gene Access Description Fold
Change*
Incidence
Cell cycle – related genes
Clk4 AF005423 CDC-like kinase 4 2.3 3/5
Cks1 AB025409 CDC28 protein
kinase 1
4.0 4/5
CDC2a M38724 CDC2 homolog A 16.0 5/5
CDC20 AW061324 CDC20 homolog 4.6 4/5
CDC25c L16926 CDC25 homolog C 5.3 4/5
Ccna2 X75483 Cyclin A2 2.6 3/5
Ccnb1 X64713 Cyclin B1 16.0 4/5
Ccnb2 X66032 Cyclin B2 2.5 3/5
Ccnd1 AI849928 Cyclin D1 2.6 4/5
Ccne1 X75888 Cyclin E1 2.5 4/5
Mad2l1 U83902 MAD2-like 1 2.6 4/5
Plk U01063 Polo-like kinase
homolog
9.1 5/5
Plk-ps1 U73170 Polo-like kinase,
pseudogene 1
2.6 4/5
Dp1 AF043939 DP1 gene 2.0 3/5
Gadd45b AV138783 GADD45 b- 4.3 5/5
Bub1 AF002823 mitotic checkpoint
protein kinase Bub1
9.6 4/5
Ras pathway effectors
Racgap1 AW122347 Rac GTPase-
activating protein 1
3.5 4/5
Rad51 D13803 RAD51 homolog
(Saccharomyces
cerevisiae)
2.3 3/5
Rad9 AF045663 RAD9 homolog
(S. pombe)
8.6 5/5
Ranbp1 X56045 RAN-binding
protein 1
2.1 3/5
Rap2ip U73941 Rap2-interacting
protein
2.8 4/5
Rin2 AI835968 Ras and Rab
interactor 2
2.9 3/5
Rassf1 AW049415 RalGDS/AF-6
domain family 1
2.8 4/5
Rasgrp1 AF106070 RAS guanyl
releasing protein 1
4.0 5/5
Arhg AB025943 Ras homolog gene
family, member G
2.5 5/5
Arhh AA739233 Ras homolog gene
family, member H
2.9 5/5
Arhj AW121127 Ras homolog gene
family, member J
2.0 4/5
Rasl2-9 L32752 RAS-like, family 2,
locus 9
2.8 3/5
Rac3 AA967636 RAS-related C3
Botulinum
substrate 3
10.5 4/5
Arhgef1 U58203 Rho GEF 1 2.5 4/5
Rhoip3 AV277546 Rho-interacting
protein 3
6.5 4/5
Transcription regulators
Atf3 U19118 Activating transcription
factor 3
5.3 5/5
Elk4 Z36885 ELK4, member of ETS
oncogene family
3.3 3/5
Etv1 L10426 Ets variant gene 1 2.1 3/5
Etv4 X63190 Ets variant gene 4
(E1AF)
4.9 5/5
Etv6 AI845538 Ets variant gene 6
(TEL oncogene)
2.1 3/5
Foxc2 AV251191 Forkhead box C2 4.0 5/5
Foxm1 Y11245 Forkhead box M1 2.0 4/5
Fosl1 AF017128 Fos-like antigen 1 9.8 5/5
Jun X12761 Jun oncogene 7.5 5/5
Table 2. Continued.
Gene Access Description Fold
Change*
Incidence
Nfkb1 M57999 NF-nB1, p105 2.2 4/5
Nfkbie AF030896 InB epsilon 3.9 4/5
Mybbp1a U63648 MYB-binding protein
(P160) 1a
4.3 4/5
Nmi AF019249 N-myc (and STAT)
interactor
2.3 3/5
EGF/EGFR pathway
Egfr AW049716 Epidermal growth
factor receptor
2.6 4/5
Mapk10 L35236 Mitogen-activated
protein kinase 10
2.3 3/5
Map4k4 U88984 MAP kinase kinase
kinase kinase 4
2.0 3/5
Mknk1 Y11091 MAPK-interacting
serine/threonine
kinase 1
4.3 5/5
Scap2 AB014485 Src family –associated
phosphoprotein 2
2.3 4/5
Shd AB018423 Src homology
2– transforming
protein D
3.0 4/5
Sla U29056 Src-like adaptor 4.6 4/5
Pik3c2a U52193 PI3 kinase, C2 domain
containing a
7.5 4/5
Pik3ca U03279 PI3 kinase, catalytic,
a-polypeptide
2.3 3/5
Most of the upregulated genes were Ras family genes, transcription factors,
cell cycle– related genes, and intracellular signaling cascade factors.
*Fold change is the ratio of mean gene expression values of the tumors to
the mean gene expression values of the epithelia from the microarray.
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[31]. Thus, the activation of PI3 kinase associated with
excessive Ras activity may promote oncogenesis by blunting
the apoptosis-inducing stimuli associated with oncogenic
transformation.
In our present study, we found that Ras superfamily mem-
bers significantly changed in mouse bladder tumorigenesis
with several GEFs overexpressed, such as RhoGEF1 and
RasGRP1, and GDIs underexpressed, including RhoGDIa
and RhoGDIc, in mouse bladder tumors, respectively. Sev-
eral EGFR–Ras pathway effectors were also found to be
overexpressed in mouse bladder tumors, including EGFR,
Ras superfamily members, Src, PI3 kinase, and downstream
transcription factors, such as Fos, Jun, NF-jB, andMyc. Our
data suggest that bladder tumors can most likely develop
through the EGFR–Ras pathway.
Another group of genes found to be differentially express-
ed in bladder tumors are cell cycle–related genes. Tumor
proliferation depends on the derangement of normal cell
cycle progression and control. Cell cycle–associated protein
complexes composed of cyclins and cyclin-dependent ki-
nases (CDKs) regulate normal cellular proliferation. Different
CDK–cyclin complexes cooperate to drive cells through dif-
ferent phases of the cell cycle. Activation of CDK4 and CDK6
by D-type cyclins is thought to be involved in progression
through early G1. CDK2 is sequentially activated by E-type
cyclins during the G1/S transition, and the A-type cyclins
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Table 3. Selected Genes Whose Expression Is Downregulated in Mouse
Bladder Tumors Compared with Normal Bladder Epithelia Identified by
Microarray.
Downregulated Genes in Mouse Bladder Tumors Identified by Microarray
Gene Access Description Fold
Change*
Incidence
Cell cycle – related genes
Ccng1 L49507 Cyclin G1 2.0 3/5
Gas1 X65128 Growth arrest– specific 1 2.8 4/5
Madh2 U60530 MAD homolog 2 2.9 5/5
Atm U43678 Ataxia telangiectasia–
mutated homolog
4.9 5/5
Rbbp7 U35142 Retinoblastoma -
binding protein 7
2.1 3/5
Rbl2 U36799 Retinoblastoma-like 2 2.0 3/5
Ras pathway effectors
Rab11a AI853996 RAB11a, member of
RAS oncogene family
2.5 3/5
Rab33b AW208630 RAB33B, member of
RAS oncogene family
2.6 5/5
Rab3d AI835706 RAB3D, member of
RAS oncogene family
2.1 4/5
Rab9 AB027290 RAB9, member of
RAS oncogene family
2.1 5/5
Arhgdia AI836322 Rho GDP dissociation
inhibitor (GDI) a
7.0 5/5
Arhgdig U73198 Rho GDP dissociation
inhibitor (GDI) gamma
2.8 4/5
Rhob X99963 rhoB gene 2.1 4/5
Arhq D50264 Ras homolog gene
family, member Q
2.6 4/5
Transcription regulators
Tbx2 U15566 T-box 2 4.0 5/5
Ndr2 AB033921 N-myc downstream-
regulated 2
21.1 5/5
Lasp1 AW122780 LIM and SH3 protein 1 2.3 4/5
Lmo1 AW124311 LIM domain only 1 6.5 5/5
Lmo4 AF074600 LIM domain only 4 2.3 4/5
Pdlim3 AF002283 PDZ and LIM domain 3 4.9 5/5
Tcf2 AB008174 Transcription factor 2 2.0 3/5
Tcf21 AF035717 Transcription factor 21 3.7 4/5
Tcf3 AJ223069 Transcription factor 3 2.5 3/5
Gata2 AB000096 GATA-binding protein 2 3.5 5/5
Gata3 X55123 GATA-binding protein 3 9.2 5/5
Gata4 M98339 GATA-binding protein 4 2.3 3/5
Cri1 AI844939 CREBBP/EP300–
inhibitory protein 1
2.3 5/5
MAPK/Src homolog
Erk2 D87271 ERK2 2.6 4/5
Map2k6 U39066 Mitogen-activated protein
kinase kinase 6
2.5 3/5
Map3k4 AV270901 Mitogen-activated protein
kinase kinase kinase 4
3.0 4/5
Map3k5 AB006787 Mitogen-activated protein
kinase kinase kinase 5
2.5 4/5
Map3k8 AV341985 Mitogen-activated protein
kinase kinase kinase 8
3.0 3/5
Sh2bpsm1 AF020526 SH2-B PH domain containing
signalingmediator 1
2.1 3/5
Sh3bgr AW048272 SH3-binding domain, glutamic
acid– rich protein
4.9 5/5
Sh3bp1 X87671 SH3 domain–binding protein 1 2.8 4/5
Sh3gl2 U58886 SH3 domain GRB2-like 2 13.0 5/5
Sh3gl3 U58887 SH3 domain GRB2-like 3 2.5 4/5
Downregulated genes include the mitogen-activated protein kinase genes,
cell cycle checkpoint genes, Rab subfamily genes, Rho subfamily genes, and
SH2 and SH3 domains– related genes.
*Fold change is the ratio of mean gene expression values of the tumors to the
mean gene expression values of the epithelia from the microarray.
Figure 2. Distribution of the 1164 differentially expressed known genes by
microarray analysis and semiquantitative RT-PCR confirmation for selected
genes. (A) Overview of the number of genes has different fold changes com-
pared with normal bladder epithelia. (B) Comparison of fold change produced
by microarray with relative expression ratio obtained from RT-PCR; the con-
cordance is good.
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during S phase [32]. CDK1/cyclin B is critical for the onset
of mitosis. Proper regulation of CDK1 (CDC2 and CDC28 in
fission and budding yeast, respectively) requires both acti-
vating and inhibitory phosphorylation [33]. Activation of tyro-
sine phosphatase CDC25 results in activation of CDK1 by
dephosphorylation on Tyr15, triggering the onset of mitosis.
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Figure 3. GenMAPP G13 and TGF-b signaling pathways integrated in the mouse bladder tumorigenesis with cutoff fold change z1.5 and P < .05. Yellow and blue
indicate overexpressed and underexpressed genes in the tumor samples, respectively. Grey indicates that the selection criteria were not met but the gene is
represented on the array. White boxes indicate that the gene was not present on the chip.
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The activity of CDK1/cyclin B is also regulated through pro-
teolysis. Anaphase-promoting complex (APC), a gatekeeper
of the spindle assemble checkpoint, can be activated by
CDC20 and activated APC can mediate the cyclin B prote-
olysis, resulting in rapid decline in CDK1 activity [34]. APC
activity is primarily regulated by MAD2, which has implicated
the BUB family of kinase. Polo kinases regulate several
stages of mitotic progression. Some of their proposed sub-
strates are CDC25C, b-tubulin, APC/C subunits, and the
kinesin-related protein MKLP-1 [35]. Cks1 promotes mitosis
by modulating the transcriptional activation of the APC/C
protein ubiquitin ligase activator CDC20. The essential role
of Cks1 is to recruit the proteasome to, and/or dissociate the
CDC28 kinase from, the CDC20 promoter, thus facilitating
transcription by remodeling transcriptional complexes or
chromatin associated with the CDC20 gene [36].
Several tumor-suppressor genes and their protein prod-
ucts (p53, pRb, p27Kip1, p16INK4A, and p14ARF) act at the G0/
G1 checkpoint of the cell cycle to prevent loss of cell cycle
control, and, ultimately, tumor progression. RBL2/p130 is a
member of the Rb family of proteins, which are structurally
and functionally similar to the pRb. Overexpression RBL2/
p130 can induce growth arrest in certain cell types [37] and
can bind to and inhibit the transcriptional activity of E2F
transcription factors [38]. RBBP7 was initially identified as a
Rb-binding protein [39] and was shown to repress E2F-
regulated promoters together with HDAC proteins and
BRG1 in a Rb-containing complex [40,41]. RBBP7 is located
on the X chromosome and it is interesting to note that rates
of bladder cancer in males exceed that in females by
approximately four-fold by the age of 60 years, with an
increasing sex difference throughout life. RBBP7 is a potent
suppressor of cell growth in transformed cell lines and
inhibits tumorigenesis in nude mice [42,43]. Expression of
this gene was decreased in tumors relative to controls. Thus,
RBBP7 may have an essential role in cell cycle control and
may act as a tumor suppressor.
In this study, the cell cycle commitment genes, such as
cyclins and CDKs, were found to be overexpressed. RBL2/
p130 and RBBP7, which act at the checkpoint and suppress
cell growth, were underexpressed in bladder tumorigenesis,
respectively. This result is in agreement with our finding of a
relatively high proliferative index in larger lesions derived
from this model. Ligand binding to EGFR may activate
the Ras pathway, resulting in induction of the cell cycle and
causing an uncontrolled cell growth.
In addition to the involvement of EGFR, Ras pathways,
and cell cycle, G13 and TGF-b signal pathways are also
involved in mouse bladder tumorigenesis (Figure 3). G13
directly interacts with and activates a GEF for the GTPase
Rho, p115RhoGEF, and thus activates Rho, leading to a
variety of effects such as the regulation of actin cytoskeleton.
G13 may also engage the PI3K pathway to activate the
protein kinase Akt and regulate NF-nB [44]. The TGF-b
pathways regulate many processes, including cellular prolif-
eration, differentiation, apoptosis, inflammation, hematopoi-
esis, wound repair, and specification of development.
Disruption of these pathways can lead to a range of dis-
eases, including cancer. TGF-b binding type I and type II
receptors on the cell surface allow receptor II to phosphory-
late the receptor I kinase domain, which then propagates the
signal through phosphorylation of the Smad proteins. The
activated Smad complexes are translocated into the nucleus
and, in conjunction with other nuclear cofactors, regulate the
transcription of target genes [45]. TGF-b switches from tumor
suppressor in the premalignant stages of tumorigenesis to
proto-oncogene at a later stage, leading to cancer progres-
sion, survival, and metastasis [46,47]. Biphasic roles of TGF-
b in signal transduction are associated with the cross-talk
between TGF-b and other signaling pathways, such as
inhibition of early EGF-induced p42/p44 MAPK, PKA–Raf1
interaction in delayed EGF-induced cell cycle [48], and Rho-
like GTPase in activation of TGF-b downstream pathways
[49,50].
In conclusion, we show in this study that microarrays can
be used to significantly enhance the search for the molecu-
lar pathogenesis of tumors. We found that inappropriate
regulation of Ras, cell cycle, and TGF-b pathways may be
the three major steps in the tumorigenesis of mouse bladder
malignancy. In addition, we were able to identify a variety of
genes whose expression was highly increased, independent
of whether they are directly involved in the mechanism of
tumorigenesis in this model. These highly modulated
genes—should they prove to be changed at the protein
level—may prove highly useful in identifying early lesions
as well as in identifying tumors in samples from urine or
serum. In addition, both these highly overexpressed genes
as well as many of the genes, which are along the mecha-
nistic pathway, may prove to be modulated by effective
preventive or therapeutic agents. Finally, with regards to
our initial question as to what is the proper control for these
studies, we may not be able to reach a definitive conclusion.
It would appear that combined use of both normal bladder
and bladder epithelia might be most useful. These results
support the relevance of OHBBN-induced bladder cancer in
mice as an in situ model of bladder cancer.
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